Blinatumomab Extends Survival for Patients with Advanced ALL



Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.



Source link

Comments are closed.